Investing.com -- Enanta Pharmaceuticals (NASDAQ:ENTA) stock fell 14% after the company announced that its experimental drug zelicapavir failed to meet the primary endpoint in a Phase 2b study for ...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) on Monday released topline data from RSVHR Phase 2b study of zelicapavir in outpatient adults with acute respiratory syncytial virus (RSV) infection who are ...

Real-world data confirm that nirsevimab provides powerful protection for infants, reducing RSV hospital stays and easing the strain on families and healthcare systems. One virus fills winter pediatric ...

This article is part of “Innovations In: RSV” an editorially independent special report that was produced with financial support from MSD, Sanofi and AstraZeneca. After my dad died, I assumed that ...

This article is part of “Innovations In: RSV,” an editorially independent special report that was produced with financial support from MSD, Sanofi and AstraZeneca. When Laura Ehrlich gave birth to her ...

TORONTO — The Ontario government is expanding the Respiratory Syncytial Virus (RSV) prevention program to include all individuals aged 75 years and older, helping to protect those most vulnerable ...

For older adults, the vaccine against respiratory syncytial virus (RSV) appears to be most effective in the first year after administration, according to new research that shows the benefits of the ...

For infants less than 8 months of age born during or entering their first RSV season and not otherwise protected through maternal vaccination, nirsevimab is considered the first-line recommended ...

Newborn babies are 80% less likely to be hospitalised with a life-threatening virus if their mother has been vaccinated in pregnancy, new research has found. Respiratory syncytial virus (RSV) is one ...

The UK Health Security Agency (UKHSA) has reported that the respiratory syncytial virus (RSV) vaccine is around 82% effective in preventing hospitalisation among adults aged 75-79. The data come from ...

Gilead Sciences has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two midstage trials of obeldesivir. The pharma had been evaluating the antiviral drug in ...